Artykuły w czasopismach na temat „Inc Catapult”
Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych
Sprawdź 37 najlepszych artykułów w czasopismach naukowych na temat „Inc Catapult”.
Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.
Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.
Przeglądaj artykuły w czasopismach z różnych dziedzin i twórz odpowiednie bibliografie.
Bishko, C. J. "St James's Catapult. The Life and Times of Diego Gelmírez of Santiago de Compostela. By R. A. Fletcher. Pp. xii + 341 inc. 2 maps. Oxford: Clarendon Press, 1984. £28." Journal of Ecclesiastical History 36, nr 4 (październik 1985): 650–52. http://dx.doi.org/10.1017/s0022046900044067.
Pełny tekst źródłaWoyach, Jennifer A., Amy S. Ruppert, Nyla A. Heerema, Weiqiang Zhao, Allison M. Booth, Wei Ding, Nancy L. Bartlett i in. "Long-Term Results of Alliance A041202 Show Continued Advantage of Ibrutinib-Based Regimens Compared with Bendamustine Plus Rituximab (BR) Chemoimmunotherapy". Blood 138, Supplement 1 (5.11.2021): 639. http://dx.doi.org/10.1182/blood-2021-153146.
Pełny tekst źródłaBannerji, Rajat, John N. Allan, Jon E. Arnason, Jennifer R. Brown, Ranjana H. Advani, Jeffrey A. Barnes, Stephen M. Ansell i in. "Clinical Activity of REGN1979, a Bispecific Human, Anti-CD20 x Anti-CD3 Antibody, in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)". Blood 134, Supplement_1 (13.11.2019): 762. http://dx.doi.org/10.1182/blood-2019-122451.
Pełny tekst źródłaVartanov, Alexander R., Stacey M. Fernandes, Winnie I. Nguy, Danielle M. Brander, Svitlana Tyekucheva, Alexandra Savell, Allison P. Jacob i in. "High Sensitivity NGS Analysis of MRD in CLL Patients Prospectively Treated with Ibrutinib Plus FCR (iFCR)". Blood 134, Supplement_1 (13.11.2019): 4291. http://dx.doi.org/10.1182/blood-2019-124305.
Pełny tekst źródłaSpangler, Rhys, Timo Rantalainen, Paul Gastin i Daniel Wundersitz. "Inertial Sensors are a Valid Tool to Detect and Consistently Quantify Jumping". International Journal of Sports Medicine 39, nr 10 (19.07.2018): 802–8. http://dx.doi.org/10.1055/s-0044-100793.
Pełny tekst źródłaNaeem, Aishath S., Winnie I. Nguy, Svitlana Tyekucheva, Stacey M. Fernandes, Vanessa Rai, Kevin Ebata, Eliana B. Gomez, Barb J. Brandhuber, Stephen M. Rothenberg i Jennifer R. Brown. "LOXO-305: Targeting C481S Bruton Tyrosine Kinase in Patients with Ibrutinib-Resistant CLL". Blood 134, Supplement_1 (13.11.2019): 478. http://dx.doi.org/10.1182/blood-2019-124362.
Pełny tekst źródłaMato, Anthony R., Kavita Sail, Maryam Sarraf Yazdy, Brian T. Hill, Mazyar Shadman, Beenish S. Manzoor, Hande H. Tuncer i in. "Treatment Sequences and Outcomes of Patients with CLL Treated with Venetoclax and Other Novel Agents Post Introduction of Novel Therapies". Blood 134, Supplement_1 (13.11.2019): 1756. http://dx.doi.org/10.1182/blood-2019-124600.
Pełny tekst źródłaShadman, Mazyar, Kavita Sail, Beenish S. Manzoor, Maryam Sarraf Yazdy, Brian T. Hill, Hande H. Tuncer, John N. Allan i in. "Treatment Discontinuation Patterns for Patients with CLL in the Real-World Settings: Results from a Multi-Center Study". Blood 134, Supplement_1 (13.11.2019): 3048. http://dx.doi.org/10.1182/blood-2019-131401.
Pełny tekst źródłaLampson, Benjamin L., Svitlana Tyekucheva, Conner J. Shaughnessy, Annette S. Kim i Jennifer R. Brown. "Incidence of Germline ATM Variants in a Consecutive Clinical Cohort of CLL Patients". Blood 134, Supplement_1 (13.11.2019): 1731. http://dx.doi.org/10.1182/blood-2019-127180.
Pełny tekst źródłaBrown, Jennifer R., Matthew S. Davids, Julie E. Chang, Shuo Ma, Juliana M. L. Biondo, Yong Mun, Madlaina Breuleux i William G. Wierda. "Outcomes of Ibrutinib (Ibr) Therapy in Ibr-Naïve Patients (pts) with Chronic Lymphocytic Leukemia (CLL) Progressing after Venetoclax (Ven)". Blood 134, Supplement_1 (13.11.2019): 4320. http://dx.doi.org/10.1182/blood-2019-123665.
Pełny tekst źródłaLiu, Vivian M., Romain Guièze, Daniel Rosebrock, Alexis A. Jourdain, María Hernández-Sánchez, Aina Zurita Martinez, Elisa Ten Hacken i in. "MCL-1 and PKA/AMPK Axis Fuel Venetoclax Resistance in Lymphoid Cancers". Blood 134, Supplement_1 (13.11.2019): 1284. http://dx.doi.org/10.1182/blood-2019-131336.
Pełny tekst źródłaAllan, John N., Krish Patel, Anthony R. Mato, William G. Wierda, Javier Pinilla Ibarz, Michael Y. Choi, Susan M. O'Brien i in. "Ongoing Results of a Phase 1B/2 Dose-Escalation and Cohort-Expansion Study of the Selective, Noncovalent, Reversible Bruton'S Tyrosine Kinase Inhibitor, Vecabrutinib, in B-Cell Malignancies". Blood 134, Supplement_1 (13.11.2019): 3041. http://dx.doi.org/10.1182/blood-2019-126286.
Pełny tekst źródłaMato, Anthony R., John M. Pagel, Catherine C. Coombs, Nirav N. Shah, Nicole Lamanna, Tahla Munir, Ewa Lech-Marańda i in. "Pirtobrutinib, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Updated Results from the Phase 1/2 BRUIN Study". Blood 138, Supplement 1 (5.11.2021): 391. http://dx.doi.org/10.1182/blood-2021-147599.
Pełny tekst źródłaFurman, Richard R., William G. Wierda, Anna Schuh, Stephen Devereux, Jorge M. Chaves, Jennifer R. Brown, Peter Hillmen i in. "Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: 42-Month Follow-up of a Phase 2 Study". Blood 134, Supplement_1 (13.11.2019): 3039. http://dx.doi.org/10.1182/blood-2019-128706.
Pełny tekst źródłaZheng, Dandan, Kavita Sail, Lindsey E. Roeker, Beenish S. Manzoor, Hande H. Tuncer, John N. Allan, Chaitra S. Ujjani i in. "Venetoclax Effectiveness, Safety, and Treatment Patterns in Chronic Lymphocytic Leukemia Patients: Results from the CLL Collaborative Study of Real-World Evidence (CORE)". Blood 136, Supplement 1 (5.11.2020): 19–22. http://dx.doi.org/10.1182/blood-2020-134676.
Pełny tekst źródłaChahal, Amandeep Kaur, Jolene Ziyuan Lim, Jing-Wen Pan i Pui Wah Kong. "Inter-Unit Consistency and Validity of 10-Hz GNSS Units in Straight-Line Sprint Running". Sensors 22, nr 5 (28.02.2022): 1888. http://dx.doi.org/10.3390/s22051888.
Pełny tekst źródłaHillmen, Peter, Jennifer R. Brown, John C. Byrd, Barbara F. Eichhorst, Nicole Lamanna, Susan M. O'Brien, Lugui Qiu i in. "Alpine: Phase 3 Trial of Zanubrutinib (BGB-3111) Vs Ibrutinib in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)". Blood 134, Supplement_1 (13.11.2019): 4307. http://dx.doi.org/10.1182/blood-2019-124213.
Pełny tekst źródłaMato, Anthony R., Ian W. Flinn, John M. Pagel, Jennifer R. Brown, Chan Y. Cheah, Catherine C. Coombs, Manish R. Patel i in. "Results from a First-in-Human, Proof-of-Concept Phase 1 Trial in Pretreated B-Cell Malignancies for Loxo-305, a Next-Generation, Highly Selective, Non-Covalent BTK Inhibitor". Blood 134, Supplement_1 (13.11.2019): 501. http://dx.doi.org/10.1182/blood-2019-127509.
Pełny tekst źródłaLancet, Jeffrey E., Farhad Ravandi, Ellen K. Ritchie, Hamid Sayar, Stephen A. Strickland, Gary J. Schiller, Norbert Vey i in. "Baseline Predictors of Mortality in Patients with Relapsed or Refractory Acute Myeloid Leukemia Treated with Vosaroxin Plus Cytarabine or Placebo Plus Cytarabine in the Phase 3 VALOR Study". Blood 126, nr 23 (3.12.2015): 2560. http://dx.doi.org/10.1182/blood.v126.23.2560.2560.
Pełny tekst źródłaBachireddy, Pavan, Christina Ennis, Vinhkhang N. Nguyen, Nikolas Barkas, Sachet Shukla, Kendell Clement, Samuel Freeman i in. "Distinct Evolutionary Patterns in Chronic Lymphocytic Leukemia (CLL) during Resistance to Graft-Versus-Leukemia (GvL)". Blood 134, Supplement_1 (13.11.2019): 516. http://dx.doi.org/10.1182/blood-2019-129520.
Pełny tekst źródłaTam, Constantine S., Ian W. Flinn, Alessandra Tedeschi, Emmanuelle Ferrant, Jennifer R. Brown, Tadeusz Robak, Paolo Ghia i in. "Zanubrutinib in Combination with Venetoclax for Patients with Treatment-Naïve Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma and del(17p): Arm D of the SEQUOIA (BGB-3111-304) Trial". Blood 136, Supplement 1 (5.11.2020): 24–25. http://dx.doi.org/10.1182/blood-2020-134179.
Pełny tekst źródłaBrown, Jennifer R., Barbara F. Eichhorst, Paolo Ghia, Arnon P. Kater, Jianyong Li, Sudha Khurana, Mostafa Elhamy, Min Hui Wang i John F. Seymour. "A Phase 3 Trial Comparing the Efficacy and Safety of Acalabrutinib in Combination with Venetoclax with or without Obinutuzumab, Compared with Investigator's Choice of Chemoimmunotherapy in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) without Del(17p) or TP53 Mutation". Blood 134, Supplement_1 (13.11.2019): 4318. http://dx.doi.org/10.1182/blood-2019-123057.
Pełny tekst źródłaCrombie, Jennifer L., Svitlana Tyekucheva, Alexandra Savell, Karen Francoeur, Mark Choiniere, Josie Montegaard, Jacob D. Soumerai i in. "A Phase I Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory CLL / SLL". Blood 134, Supplement_1 (13.11.2019): 1763. http://dx.doi.org/10.1182/blood-2019-127343.
Pełny tekst źródłaMerryman, Reid W., Robert A. Redd, Eleanor Taranto, Gulrayz Ahmed, Erin Jeter, Kristin M. McHugh, Jennifer R. Brown i in. "Prognostic Value of Circulating Tumor DNA (ctDNA) in Autologous Stem Cell Graft and Post-Transplant Plasma Samples Among Patients with Diffuse Large B-Cell Lymphoma". Blood 136, Supplement 1 (5.11.2020): 22–23. http://dx.doi.org/10.1182/blood-2020-140965.
Pełny tekst źródłaBurke, Kathleen, Barrett Nuttall, Daniel L. Karl, Megan Callahan, Kerrin Mendler, Steven Criscione, Sergey Naumenko i in. "Novel Mechanisms of Acalabrutinib Resistance in Patients with Chronic Lymphocytic Leukemia By Whole Genome Methylome Sequencing". Blood 138, Supplement 1 (5.11.2021): 4361. http://dx.doi.org/10.1182/blood-2021-147113.
Pełny tekst źródłaDavids, Matthew S., Kirsten Fischer, Sandra Robrecht, Can Zhang, Inhye E. Ahn, Michele Porro Lurà, Wendy Sinai i in. "ReVenG: A Phase 2 Study of Venetoclax Plus Obinutuzumab Retreatment in Patients with Relapsed Chronic Lymphocytic Leukemia". Blood 138, Supplement 1 (5.11.2021): 2634. http://dx.doi.org/10.1182/blood-2021-153033.
Pełny tekst źródłaLampson, Benjamin L., Svitlana Tyekucheva, Jennifer L. Crombie, Austin I. Kim, Reid W. Merryman, Jessica Lowney, Josie Montegaard i in. "Preliminary Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL)". Blood 134, Supplement_1 (13.11.2019): 32. http://dx.doi.org/10.1182/blood-2019-127506.
Pełny tekst źródłaDavids, Matthew S., Danielle M. Brander, Svitlana Tyekucheva, Chinheng Chen, James Kaminski, Josie Montegaard, Alvaro J. Alencar i in. "Longer Term Follow-up of a Multicenter, Phase 2 Study of Ibrutinib Plus Fludarabine, Cyclophosphamide, Rituximab (iFCR) As Initial Therapy for Younger Patients with Chronic Lymphocytic Leukemia". Blood 138, Supplement 1 (5.11.2021): 640. http://dx.doi.org/10.1182/blood-2021-146624.
Pełny tekst źródłaBall, William J. "Book Reviews : Beyond the Home Page Book Review Essay on Guides to Advanced Content Creation for the Web Introducing Microsoft FrontPage97. Kerry A. Lehto and W. Brett Polonsky. Redmond, WA: Microsoft Press, 1997. 384 pp., $24.99. Microsoft FrontPage97 Step by Step. Catapult Inc. Redmond, WA: Microsoft Press, 1997. 286 pp., $29.99. Web Scripting Secret Weapons. Scott Walker. Indianapolis, IN: Que Corp., 1997. 380 pp., $39.99. Special Edition Using JavaScript. Mark C. Reynolds. Indianapolis, IN: Que Corp., 1997. 831 pp., $49.99. VBScript by Example. Jerry Honeycutt. Indianapolis, IN: Que Corp., 1997. 355 pp., $34.99. Building VRML Worlds. Ed Tittle, Charlie Scott, Paul Wolfe, and Claire Sanders. Berkeley, CA: Osborne/McGraw Hill, 1997. 381 pp., $39.95". Social Science Computer Review 15, nr 4 (grudzień 1997): 446–50. http://dx.doi.org/10.1177/089443939701500411.
Pełny tekst źródłaSeymour, John F., John C. Byrd, Peter Hillmen, Paolo Ghia, Arnon P. Kater, Asher Chanan-Khan, Richard Furman i in. "Characterization of Bruton Tyrosine Kinase Inhibitor (BTKi)-Related Adverse Events in a Head-to-Head Trial of Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia (CLL)". Blood 138, Supplement 1 (5.11.2021): 3721. http://dx.doi.org/10.1182/blood-2021-146228.
Pełny tekst źródłaTedeschi, Alessandra, Emmanuelle Ferrant, Ian W. Flinn, Constantine S. Tam, Paolo Ghia, Tadeusz Robak, Jennifer R. Brown i in. "Zanubrutinib in Combination with Venetoclax for Patients with Treatment-Naïve (TN) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with del(17p): Early Results from Arm D of the SEQUOIA (BGB-3111-304) Trial". Blood 138, Supplement 1 (5.11.2021): 67. http://dx.doi.org/10.1182/blood-2021-144336.
Pełny tekst źródłaBrown, Jennifer R., Tadeusz Robak, Paolo Ghia, Brad S. Kahl, Patricia Walker, Wojciech Janowski, Henry Chan i in. "Efficacy and Safety of Zanubrutinib in Patients with Treatment-Naïve (TN) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with del(17p): Follow-up Results from Arm C of the SEQUOIA (BGB-3111-304) Trial". Blood 136, Supplement 1 (5.11.2020): 11–12. http://dx.doi.org/10.1182/blood-2020-134280.
Pełny tekst źródłaTam, Constantine S., Krzysztof Giannopoulos, Wojciech Jurczak, Martin Šimkovič, Mazyar Shadman, Anders Österborg, Luca Laurenti i in. "SEQUOIA: Results of a Phase 3 Randomized Study of Zanubrutinib versus Bendamustine + Rituximab (BR) in Patients with Treatment-Naïve (TN) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)". Blood 138, Supplement 1 (5.11.2021): 396. http://dx.doi.org/10.1182/blood-2021-148457.
Pełny tekst źródłaMakar, Piotr, Ana Filipa Silva, Rafael Oliveira, Marcin Janusiak, Przemysław Parus, Małgorzata Smoter i Filipe Manuel Clemente. "Assessing the agreement between a global navigation satellite system and an optical-tracking system for measuring total, high-speed running, and sprint distances in official soccer matches". Science Progress 106, nr 3 (lipiec 2023). http://dx.doi.org/10.1177/00368504231187501.
Pełny tekst źródłaWatts, Sophie P., Martyn J. Binnie, Paul SR Goods, Matthew M. Doyle, Jamie Hewlett i Peter Peeling. "Garmin wearable device offers reliable alternative for on-water stroke rate and velocity measurement in rowing". Proceedings of the Institution of Mechanical Engineers, Part P: Journal of Sports Engineering and Technology, 18.05.2022, 175433712210993. http://dx.doi.org/10.1177/17543371221099364.
Pełny tekst źródłaKenawy, A., MY Khanji, M. Chirvasa, K. Fung, A. Sojoudi, JOSE M. Paiva, N. Samy, W. Farid, TS Khalil i SE Petersen. "Application of a machine learning contouring tool for the evaluation of left ventricular strain in clinical practice". European Heart Journal - Cardiovascular Imaging 22, Supplement_1 (1.01.2021). http://dx.doi.org/10.1093/ehjci/jeaa356.259.
Pełny tekst źródłaSexton-Finck, Larissa. "Violence Reframed: Constructing Subjugated Individuals as Agents, Not Images, through Screen Narratives". M/C Journal 23, nr 2 (13.05.2020). http://dx.doi.org/10.5204/mcj.1623.
Pełny tekst źródła